Cultivate

Legal insights from leading hemp and CBD lawyers

What's NewEducation ResourcesLitigation Tracker Sub-MenuMislabeling & Advertising ClaimsMedical & Health ClaimsShareholder LitigationDietary Supplement ClaimsLabor & Employment ClaimsIntellectual PropertyProduct Liability Claims

Subscribe

Subscribe By Email

Your website url

Blog Managers

Christopher GismondiOf Counsel

Jae KimAssociate, FDA Regulatory Group

Jarred ReilingOf Counsel

Kelsey TavaresAssociate

Blog Authors Show/Hide

Kristin Beale
Stuart Brown
Christian Chessman
Maggie Craig
Stefanie Fogel
Melissa Gilmore
Christopher Gismondi
Jeffrey Hare
Jae Kim
Sharon Lindan Mayl
Wendy Michael
Jarred Reiling
Kelsey Tavares

Additional Topics

Your website url

Stay Connected

RSS Twitter LinkedIn Facebook YouTube Instagram Slideshare WeChat

Links & Resources

DLA Piper's Hemp and Hemp Regulated Products/CBD sector

Recent Posts

HHS to DEA: Marijuana Should Be Schedule III – What This Means for The Cannabis Industry
Two hemp-derived CBD bills are re-introduced despite FDA’s call for a different legislative fix
FDA seems willing to make room for a drug ingredient in a supplement, but what does that mean for CBD? NAC and the Drug Exclusion Clause of 201(ff)
A Green Light for Canna-Research? Medical Marijuana and CBD Research Bill on the Cusp
Federal Agencies’ Current Positions on Hemp-Derived CBD Products

Legal NoticesPrivacy PolicyCookie Policydlapiper.com

RSS Twitter LinkedIn Facebook YouTube Instagram Slideshare WeChat

Copyright © 2024, DLA Piper. DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper’s structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.

Law blog design & platform by LexBlog